Promising treatment success in patients with severe COVID-19 courses
Hennigsdorf, 21.04.2021 – Pentracor GmbH, a medical technology company based in Hennigsdorf near Berlin (convertible bond ISIN: DE000A289XB9, WKN: A289XB), active in the dynamically growing healthcare sector, has achieved further promising treatment successes with its CE-certified and patent-protected medical product PentraSorb® CRP in patients with severe COVID-19 courses. For example, the Havelhöhe Community Hospital in Berlin has been using Pentracor's new therapeutic extracorporeal treatment method for severely ill COVID-19 patients for several weeks and has already achieved a significant improvement in the patients' clinical condition after a short period of time.
CRP apheresis at the Klinikum Havelhöhe shown in the rbb Abendschau
17.04.2021
COVID-19 patients are treated with CRP apheresis at the Klinikum Havelhöhe. This was featured in the rbb Abendschau.
'European Hospital' reports of CRP apheresis in Covid-19
25.01.2021
The page 'Healthcare in Europe' reported about the recently successfully treated COVID-19 patient.
Report about COVID-19 patient, who was successfully treated with the PentraSorb®
20.01.2021
The Märkische Oderzeitung reported about a recently successfully treated COVID-19 patient. The patient was treated 4 times with CRP apheresis and is recovering rapidly from the disease. The article describes that the therapy most likely saved the patient from intensive care medical treatment.
Feature about CRP apheresis in the magazine rbb PRAXIS
13.01.2021
The use of CRP apheresis in COVID-19 patients was presented once again in the rbb PRAXIS magazine.
The feature reports the recent successful treatment of a COVID-19 patient with apheresis. In addition, Prof. Dr. Kielstein from the Braunschweig Clinic advocates for the therapy.
Published Papers
Clinical trial CRP apheresis after myocardial infarction published
11.03.2021
Results of the first clinical trial of CRP apheresis after acute myocardial infarction (CAMI1) were published in the cardiology journal Frontiers in Cardiovascular Medicine.
"CRP apheresis as anti-inflammatory therapy for acute myocardial infarction: results from the CAMI-1 trial."
The article describes that C-reactive protein substantially triggers myocardial damage after myocardial infarction.
Review on the pathomechanism of CRP published
10.02.2021
"C-reactive protein triggers cell death in ischemic cells":
In the Research Topic "Diagnostic and Therapeutic Applications of Pentraxin and Pentraxin-Associated Proteins" of the journal Frontiers in Immunology, a review on the pathomechanism of CRP in organ-damaging inflammation was published.
Review on CRP apheresis published
12.09.2020
In this article, the current scientific knowledge of the pathological function of CRP is concisely summarized and the therapeutic concept of CRP apheresis is explained in detail on the basis of the clinical CAMI-1 study (after myocardial infarction) and CASTRO-1 study (after stroke).
Direct effect of CRP on blood pressure and gene regulation published
30.08.2020
In the scientific journal Frontiers in Immunology an article was published in which the effect of human CRP on blood pressure and heart rate of rabbits was investigated.
COVID-19 - CRP apheresis as a treatment option
Webinars
Teaser for the webinar "Anti-inflammatory strategies for COVID-19"
Dezember 2020
Here is a “short” teaser to record our webinar on anti-inflammatory strategies for COVID-19, which is intended to provide an overview of what we believe to be the most exciting topics, key messages and areas of conflict at the event.
1st Webinar about CRP apheresis in COVID-19
14.12.2020
Pentracor GmbH recently held its first webinar with renowned physicians from Germany and Switzerland to discuss the increasingly clear relevance of the pathological function of CRP in the inflammatory, severe phase of COVID-19.
Events
Industry Symposium at the DGK
07.04.2021
An Industry Symposium about CRP, Lp(a) and Hydration is organized by Pentracor together with Kaneka at the 87th Annual Meeting of the DGK.
Care Sympsoium at the ISFA/E-ISFA about CRP apheresis
20.03.2021
Pentracor organizes a Care Symposium about CRP apheresis at the 13th ISFA & E-ISFA Congress.
Awards
2nd place for Prof. Torzewski at the GMA
18.11.2020
He was awarded in the category 'Medical Innovation Practices & Clinics - Cardiology' for the application of the innovative CRP apheresis after myocardial infarction. He prevailed against almost all colleagues, in particular also from university hospitals and heart centers.
Project "C-reactive protein and cardiovascular diseases" was nominated for the German Medical Award
01.10.2020
We are pleased to announce that Prof. Dr. Jan Torzewski of the Klinikum Kempten and Klinik Immenstadt from the Klinikverbund Allgäu has been nominated for the German Medical Award.
CAMI1 study was Highlight at the 85th DGK Annual Meeting
27.04.2019
Das Poster “Selective CRP apheresis as a new treatment option in STEMI: Final results of the CAMI1 Study” von der CAMI1-Studiengruppe wurde als Highlight der DGK Jahrestagung im Bereich “Interventionelle Kardiologie” vorgestellt.
Abstract prize at the DGfN Annual Meeting 2018
25.07.2018
The abstract "Selective CRP apheresis as a new therapeutic option in the treatment of acute myocardial infarction (STEMI)" by Dr. Wolfgang Ries was awarded as one of the 10 best at the 10th Annual Meeting of the German Society for Nephrology (DGfN) 2018.
Poster prize at 84th Annual Meeting of DGK
07.04.2018
The poster "Selective CRP apheresis as a new treatment option in acute myocardial infarction (CAMI1 study)" by Prof. Dr. Christoph Garlichs was awarded a poster prize at the 84th Annual Meeting of the DGK.
Other
Pentracor donates Corona rapid tests to the Berliner Stadtmission
03.12.2020
To meet the strict hygiene requirements for emergency overnight stays, the Berliner Stadtmission has an increasing need for Corona rapid tests for guests and staff.
The 100th patient was successfully treated with CRP apheresis
14.10.2020
Der 100. Patient wurde dieser Tage mit der CRP-Apherese behandelt. Diese Behandlung lief im Rahmen der CABY1-Studie (CRP-Apherese nach koronarer Bypass-Operation) und wurde wie gewohnt sicher durchgeführt. Wir freuen uns, dass nun schon 100 Patienten von der Therapie profitieren konnten und hoffen, noch zahlreichen weiteren Menschen helfen zu können.
Pentracor GmbH celebrates its 10th anniversary!
25.08.2010
On August 25, 2010, Dr. Ahmed Sheriff together with Birgit Vogt, Dr. Rudolf Kunze, Stephan Hiller and Dr. Bernd Wegener founded Pentracor GmbH to implement the idea of CRP apheresis for acute inflammation-driven diseases such as myocardial infarction.
